Literature DB >> 6332573

In vitro interactions between rifampin and ampicillin or chloramphenicol against Haemophilus influenzae.

T Jadavji, C G Prober, R Cheung.   

Abstract

Twenty clinical isolates of Haemophilus influenzae type b were used to determine the in vitro interactions of rifampin with ampicillin or chloramphenicol. Potential interactions of the drugs were evaluated by calculating the fractional inhibitory concentration index and fractional bactericidal concentration index for each strain after treatments with the drugs alone and in combination. There was no evidence of synergy or antagonisms between ampicillin and rifampin or between chloramphenicol and rifampin. With ampicillin-susceptible H. influenzae type b strains, an additive effect was observed with seven strains, and an indifferent effect was observed with three strains. Similarly, with chloramphenicol-susceptible H. influenzae type b strains, an additive effect was observed with eight strains, and an indifferent effect was observed with two strains.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332573      PMCID: PMC179924          DOI: 10.1128/AAC.26.1.91

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Haemophilus influenzae type B disease in a day care center: eradication of carrier state by rifampin.

Authors:  D M Granoff; J Gilsdorf; C Gessert; M Basden
Journal:  Pediatrics       Date:  1979-03       Impact factor: 7.124

Review 2.  Systemic Haemophilus influenzae disease: an overview.

Authors:  A S Dajani; B I Asmar; M C Thirumoorthi
Journal:  J Pediatr       Date:  1979-03       Impact factor: 4.406

3.  Ampicillin-resistant Hemophilus influenzae in Canada: nationwide survey of hospital laboratories.

Authors:  D W Scheifele
Journal:  Can Med Assoc J       Date:  1979-07-21       Impact factor: 8.262

4.  Prevalence of ampicillin-resistant strains of Haemophilus influenzae causing systemic infection.

Authors:  S J Lerman; J M Brunken; M Bollinger
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

5.  In-vitro bactericidal synergism of rifampicin and trimethoprim and implications for treatment of carriers of Haemophilus influenzae.

Authors:  L K McDougal; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  1982-05       Impact factor: 5.790

6.  Antagonism between nafcillin or oxacillin and rifampin against Staphylococcus aureus.

Authors:  C Watanakunakorn; J C Tisone
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

7.  An outbreak of Hemophilus influenzae type b meningitis in an enclosed hospital population.

Authors:  M P Glode; M S Schiffer; J B Robbins; W Khan; C U Battle; E Armenta
Journal:  J Pediatr       Date:  1976-01       Impact factor: 4.406

8.  Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus.

Authors:  M A Sande; M L Johnson
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

9.  In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus.

Authors:  C U Tuazon; M Y Lin; J N Sheagren
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

10.  Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes.

Authors:  A M Jezequel; F Orlandi; L T Tenconi
Journal:  Gut       Date:  1971-12       Impact factor: 23.059

View more
  3 in total

1.  Short course single daily ceftriaxone monotherapy for acute bacterial meningitis in children: results of a Swiss multicenter study. Part II: Bacteriological results.

Authors:  P Hohl; E Martin; F H Kayser
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

2.  In vitro synergism of rifampin-cephalosporin combinations against Haemophilus influenzae type b.

Authors:  R C Gordon; R Wofford-McQueen; K Shu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

3.  Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics.

Authors:  S Y Yoon; S K Eo; Y S Kim; C K Lee; S S Han
Journal:  Arch Pharm Res       Date:  1994-12       Impact factor: 4.946

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.